Industry News

FDA Approves Avapritinib for Indolent Systemic Mastocytosis

On May 22, the U.S. Food and Drug Administration (FDA) approved avapritinib for the treatment of adults with indolent systemic mastocytosis.

For more information, read the Blueprint Medicines announcement.

Posted 5/24/2023

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us